170 related articles for article (PubMed ID: 31935317)
1. Hypercalcemia of Malignancy in a Patient with Hypoparathyroidism: A Complicated but Treatable Condition.
Sierra M; Alvarado M; Ramírez M; González L; Bueno S
P R Health Sci J; 2019 Dec; 38(4):275-277. PubMed ID: 31935317
[TBL] [Abstract][Full Text] [Related]
2. From hypocalcemia to hypercalcemia-an unusual clinical presentation of a patient with permanent postsurgical hypoparathyroidism.
Sundaresh V; Levine SN
J Clin Endocrinol Metab; 2015 Jan; 100(1):21-4. PubMed ID: 25303492
[TBL] [Abstract][Full Text] [Related]
3. Successful Management of Severe Hypercalcemia with Zoledronic Acid: A Report of Two Pediatric Cases.
Kilci F; Jones JH; Çizmecioğlu-Jones FM
J Clin Res Pediatr Endocrinol; 2024 May; 16(2):224-228. PubMed ID: 36264042
[TBL] [Abstract][Full Text] [Related]
4. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
5. Zoledronate-responsive calcitriol-mediated hypercalcemia in a 5-year-old case with squamous cell carcinoma on the background of xeroderma pigmentosum.
Colak U; Mutlu GY; Sozmen BO; Yucel EB; Kayserili H; Hatun S
J Pediatr Endocrinol Metab; 2019 Dec; 32(12):1403-1406. PubMed ID: 31782950
[TBL] [Abstract][Full Text] [Related]
6. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
McMahan J; Linneman T
Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
[TBL] [Abstract][Full Text] [Related]
7. Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study.
Nasser SM; Sahal A; Hamad A; Elazzazy S
J Oncol Pharm Pract; 2019 Dec; 25(8):1846-1852. PubMed ID: 31694497
[TBL] [Abstract][Full Text] [Related]
8. Humoral hypercalcemia of pregnancy treated with bisphosphonates.
Koren R; Neeman O; Koren S; Benbassat CA
Arch Endocrinol Metab; 2018 Feb; 62(1):125-128. PubMed ID: 29694631
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid. A bisphosphonate for hypercalcemia of malignancy and osteolytic metastases.
Massaro AM
Cancer Pract; 2002; 10(4):219-21. PubMed ID: 12100107
[No Abstract] [Full Text] [Related]
10. Successful treatment of vitamin D unresponsive hypoparathyroidism with multipulse subcutaneous infusion of teriparatide.
Puig-Domingo M; Díaz G; Nicolau J; Fernández C; Rueda S; Halperin I
Eur J Endocrinol; 2008 Nov; 159(5):653-7. PubMed ID: 18703565
[TBL] [Abstract][Full Text] [Related]
11. Use of Zoledronic Acid in a Neonate with Subcutaneous Fat Necrosis Complicated with Severe, Refractory Hypercalcemia.
Militello MA; Re MP; Vitaliti G; Finazzo F; Manzoni P; Vitaliti SM
Am J Perinatol; 2019 Jul; 36(S 02):S134-S138. PubMed ID: 31238374
[TBL] [Abstract][Full Text] [Related]
12. Liver granulomatosis is not an exceptional cause of hypercalcemia with hypoparathyroidism in dialysis patients.
Hardy P; Morinière PH; Tribout B; Hamdini N; Marié A; Bouffandeau B; Pruna A; Fournier A
J Nephrol; 1999; 12(6):398-403. PubMed ID: 10626831
[TBL] [Abstract][Full Text] [Related]
13. Prolonged hypocalcaemia after pamidronate infusion in Riedel's thyroiditis associated hypoparathyroidism.
Boumans D; de Vries PA; Rikken NE; Laverman GD
Neth J Med; 2013 Oct; 71(8):442-3. PubMed ID: 24127509
[No Abstract] [Full Text] [Related]
14. Treatment of Hypercalcemia of Malignancy.
Chakhtoura M; El-Hajj Fuleihan G
Endocrinol Metab Clin North Am; 2021 Dec; 50(4):781-792. PubMed ID: 34774248
[TBL] [Abstract][Full Text] [Related]
15. [Preclinical and clinical profile of zoledronic acid (Zometa) for hypercalcemia of malignancy].
Tomoo T; Suzuki M
Nihon Yakurigaku Zasshi; 2005 Nov; 126(5):353-7. PubMed ID: 16394581
[No Abstract] [Full Text] [Related]
16. Increased 1,25-(OH)2D2 concentration in a patient with malignancy-associated hypercalcemia receiving intravenous hyperalimentation inadvertently supplemented with vitamin D2.
Sato K; Imaki T; Toraya S; Demura H; Tanaka M; Kasajima T; Takeuchi A; Kobayashi T
Intern Med; 1993 Nov; 32(11):886-90. PubMed ID: 8012094
[TBL] [Abstract][Full Text] [Related]
17. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
Guay DR
Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
[TBL] [Abstract][Full Text] [Related]
18. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S
Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601
[TBL] [Abstract][Full Text] [Related]
19. A case of myeloma with hypercalcemia caused by high serum concentrations of both parathyroid hormone-related peptide (PTHrP) and macrophage inflammatory protein-1α (MIP-1α).
Shimizu H; Monden T; Tomotsune T; Nakatani Y; Domeki N; Matsumura M; Jojima T; Kawagoe Y; Kasai K
Intern Med; 2011; 50(24):2993-6. PubMed ID: 22185991
[TBL] [Abstract][Full Text] [Related]
20. Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia.
Endo K; Katsumata K; Iguchi H; Kubodera N; Teramoto T; Ikeda K; Fujita T; Ogata E
J Bone Miner Res; 1998 Sep; 13(9):1378-83. PubMed ID: 9738509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
